Managing H1N1 Expectations: Avoiding Peak-Trough Financial Syndrome
This article was originally published in RPM Report
Big government contracts can be bittersweet financial events. The sudden influx of contracts in the hundreds of millions is dramatic version of public stimulus for the vaccine business, but automatically raises a tough question from the financial community: how will you match that in the future?
You may also be interested in...
FDA faces the massive task of facilitaing the development and distribution of H1N1 vaccine in the autumn of 2009, but the agency also has some important pending applications for other vaccines in the same timeframe: Prevnar-13, Cervarix, and Gardasil for boys. Wall Street is not showing much excitement about the upcoming decisions. The applicatins could present some pleasant surprises and positive events for the sponsors.
GSK's Cervarix HPV vaccine is going to miss another back-to-school vaccination season in the US, giving Merck even more time to cement its lead with Gardasil. The delay surprised Wall Street-but shouldn't have. FDA is exercising caution about the approval of a second HPV vaccine - one containing a new active adjuvant. The final approval will set new standards for the coming wave of adjuvant-enhanced vaccines.
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.